Lee Ainslie Maverick Capital
Lee Ainslie is the founder of Maverick Capital, a long/short equity firm that emerged from the Tiger Management network of investors. Maverick is known for fundamental research, sector specialization among teams, and a classic hedge fund long/short structure. Ainslie’s firm remains a reference name among so-called Tiger Cub managers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$157M |
| 2 |
Microsoft
MSFT
|
+$146M |
| 3 |
Advanced Micro Devices
AMD
|
+$125M |
| 4 |
Capital One
COF
|
+$119M |
| 5 |
Huntington Ingalls Industries
HII
|
+$86.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCHW
Charles Schwab
SCHW
|
+$112M |
| 2 |
Monster Beverage
MNST
|
+$102M |
| 3 |
Meta Platforms (Facebook)
META
|
+$101M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$93.4M |
| 5 |
Dollar Tree
DLTR
|
+$78M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.01% |
| 2 | Consumer Discretionary | 18.97% |
| 3 | Healthcare | 15.83% |
| 4 | Financials | 11.93% |
| 5 | Consumer Staples | 8.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Warner Bros
WBD
$71.6B
| $77.9M | 1.17% |
+6,797,230
| New | +$63.4M |
|
27
Danaher
DHR
$154B
| $73.5M | 1.1% |
372,126
-326,614
| -47% | -$63.3M |
|
28
Teva Pharmaceuticals
TEVA
$43.5B
| $73.4M | 1.1% |
4,377,690
+4,347,398
| +14,352% | +$70.2M |
|
|
PRMB
29
Primo Brands
PRMB
$8.37B
| $72M | 1.08% |
2,431,869
+491,794
| +25% | +$15.7M |
|
30
UnitedHealth
UNH
$350B
| $70.6M | 1.06% |
226,153
+79,235
| +54% | +$30.3M |
|
31
Datadog
DDOG
$84.6B
| $69.3M | 1.04% |
+516,079
| New | +$57.1M |
|
|
SGI
32
Somnigroup International
SGI
$13.6B
| $67.7M | 1.02% |
994,560
-46,058
| -4% | -$2.9M |
|
33
Coupang
CPNG
$29.6B
| $63M | 0.95% |
2,102,777
-76,418
| -4% | -$1.96M |
|
34
Acadia Healthcare
ACHC
$2.59B
| $57.9M | 0.87% |
2,553,237
+306,314
| +14% | +$7.26M |
|
|
GAP
35
The Gap Inc
GAP
$7.13B
| $54.6M | 0.82% |
2,502,118
-259,778
| -9% | -$5.81M |
|
36
lululemon athletica
LULU
$13.7B
| $54M | 0.81% |
227,110
-145,195
| -39% | -$40M |
|
37
Wave Life Sciences
WVE
$1.04B
| $53.7M | 0.81% |
8,261,683
| – | – |
|
|
VRNA
38
DELISTED
Verona Pharma
VRNA
| $49.4M | 0.74% |
521,859
-1,261,639
| -71% | -$93.4M |
|
39
Eli Lilly
LLY
$1.12T
| $45.9M | 0.69% |
+58,901
| New | +$45.8M |
|
40
Evercore
EVR
$11.2B
| $45.8M | 0.69% |
+169,745
| New | +$37.3M |
|
41
Mercado Libre
MELI
$97.5B
| $45.7M | 0.69% |
17,492
-1,432
| -8% | -$3.34M |
|
|
CRWV
42
CoreWeave
CRWV
$48.5B
| $43.7M | 0.66% |
267,740
-594,076
| -69% | -$54.8M |
|
43
Vaxcyte
PCVX
$9.32B
| $42.6M | 0.64% |
1,310,605
+102,512
| +8% | +$3.36M |
|
44
Roblox
RBLX
$27.4B
| $41.5M | 0.62% |
+394,875
| New | +$31M |
|
45
LPL Financial
LPLA
$28.5B
| $37.3M | 0.56% |
99,507
-221,273
| -69% | -$77.5M |
|
46
Viridian Therapeutics
VRDN
$2.75B
| $31.6M | 0.47% |
2,257,010
+195,736
| +9% | +$2.66M |
|
47
NewAmsterdam Pharma
NAMS
$3.33B
| $27.7M | 0.42% |
1,531,874
+982,405
| +179% | +$17.9M |
|
|
SAIL
48
SailPoint Inc
SAIL
$10.6B
| $22.1M | 0.33% |
966,050
| – | – |
|
49
Rocket Pharmaceuticals
RCKT
$385M
| $20.5M | 0.31% |
8,363,813
+3,164,595
| +61% | +$16M |
|
50
Evolent Health
EVH
$536M
| $15.7M | 0.24% |
+1,392,524
| New | +$12.8M |
|
Similar funds
Lee Ainslie's Q2 2025 Portfolio in Review
As of Q2 2025, Lee Ainslie held 316 positions worth $6.66B, up 18% from $5.66B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Lee Ainslie's Q2 2025 filing shows 81 new, 38 increased, 44 reduced and 65 closed positions. Its largest new stake was Walt Disney: 1,508,487 shares worth $187M. The largest sale was Charles Schwab, an estimated $112M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Lee Ainslie's largest Q2 2025 buy was Walt Disney: 1,508,487 shares worth $187M.
- Lee Ainslie added most to Microsoft in Q2 2025, an estimated $146M increase.
- Lee Ainslie's biggest Q2 2025 reduction was Verona Pharma, cutting an estimated $93.4M.
- Lee Ainslie fully exited Charles Schwab in Q2 2025, selling an estimated $112M.
- Lee Ainslie's ten largest holdings make up 47% of its $6.66B portfolio in Q2 2025.
- Lee Ainslie opened 81 new positions and closed 65 in Q2 2025.
- Lee Ainslie's portfolio value rose 18% quarter-over-quarter to $6.66B.
Based on Maverick Capital's 13F filing for Q2 2025, filed 14 Aug 2025.